April sixteenthRoyalcasinovideopokerA symposium on the innovation and development of medical robots was held in Changping, Beijing.

The meeting exchanged information on the research and development of medical robots, focused on the common issues of innovation and development, and discussed supporting policies.

Xu Jinghe, member of the party leading group and deputy director of the State Drug Administration, attended.

Xu Jinghe pointed out that medical robots, as the representative of new productivity in the field of medical devices, are the key areas supported by various departments.

The State Drug Administration will further strengthen cooperation among ministries, promote the coordinated development of industry, university, medical and research management, study and introduce targeted measures, speed up the marketing and application of iconic products, and promote the development of medical robots with high quality through scientific supervision. better meet the needs of public health.

Medical robot related enterprises:

Minimally invasive Robot-B (02252): announced on the Hong Kong Stock Exchange that the company and France's Robocath SRoyalcasinovideopokerThe R-ONE vascular interventional surgery robot introduced by .A.S joint venture Zhimai (Shanghai) Robot Co., Ltd. in China has been approved by the State Drug Administration. The Swan Orthopaedic Joint replacement Navigation and Positioning system (Swan Hip and knee Arthroplasty Robot) independently developed by the Group has been officially approved by the State Drug Administration (NMPA), becoming the first domestic hip and knee orthopaedic surgery robot equipped with a self-developed manipulator.